Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients

1 Oct 2019

Abstract excerpt

BACKGROUND: Gliomas are the most frequently occurring malignant brain cancers. Recently, isocitrate dehydrogenase (IDH) mutations, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and 1p/19q co-deletion have been suggested to indicate a favorable prognosis in gliomas. However, the clinical prognostic value of these genetic tests in human gliomas is not fully understood. METHODS: We included...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31807523
DOI: 10.21037/atm.2019.09.126

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patientsPMID 31807523Read ↗

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.Semantic proximity Read ↗

Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.Semantic proximity Read ↗

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.Semantic proximity Read ↗

The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?Semantic proximity Read ↗

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.Semantic proximity Read ↗

Diagnostic and prognostic markers in gliomas - an update.Semantic proximity Read ↗

Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling.Semantic proximity Read ↗

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.Semantic proximity Read ↗

Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.Semantic proximity Read ↗

Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese CenterSemantic proximity Read ↗

Predictive and prognostic factors for gliomas.Semantic proximity Read ↗

[Advance of molecular subtyping and precise treatment for gliomas].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.